Previous 10 | Next 10 |
Arvinas (NASDAQ: ARVN ) initiated with Buy rating and $35 (23% upside) price target at Roth Capital. More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Harpoon Therapeutics (NASDAQ: HARP ): Q3 GAAP EPS of -$0.65 misses by $0.09 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Continued enrollment and dose escalation of Phase 1 trial for HPN424 and Phase 1/2a trial for HPN536, Harpoon’s lead TriTAC ® product candidates in development for the treatment of prostate and ovarian and pancreatic cancers, respectively. Preclinical data present...
HPN328, a TriTAC ® , Exhibits the Potency, Tolerability, and Pharmacokinetics to Support Initiation of Clinical Development in 2020 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company develop...
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract regarding HPN328 for the treatment of small cell lung cancer has bee...
The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with this Read more ...
Harpoon Therapeutics (NASDAQ: HARP ): Q2 GAAP EPS of -$0.49 beats by $0.16 . More news on: Harpoon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Continued enrollment and dose escalation of Phase 1 trial for HPN424, Harpoon’s lead TriTAC product candidate in development for the treatment of prostate cancer Initiated Phase 1/2a clinical trial for HPN536, Harpoon’s second TriTAC product candidate IND submission for HPN...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...